Peplin obtains positive anti-leukemia results for drug candidate in mouse model
13 October, 2005 by Helen SchullerPeplin (ASX:PEP) has produced positive results from an initial efficacy study of its drug candidate PEP005 IV in a mouse model of acute myeloid leukemia.
Money flows back into Australian biotech stocks: Intersuisse
11 October, 2005 by Ruth BeranCash is finally flowing towards biotechnology and medical device stocks after a long and sustained drought, according to Intersuisse biotechnology index for the quarter ended September 2005.
GM flu-resistant chooks solution to pandemic threat - British scientist
07 October, 2005 by Graeme O'NeillIt would take only four years to completely replace today's farmed chickens with genetically modified breeds fully resistant to infection to avian influenza, according to a visiting British molecular virologist.
pSivida acquires US drug delivery company
04 October, 2005 by Helen SchullerPerth nano-biotech company pSivida (ASX:PSD; NASDAQ:PSDV; Xetra:PSI) has agreed to purchase privately owned US drug delivery company Control Delivery Systems (CDS) for US$104 million (AUD$139 million), as part of its on-going US growth strategy.
Another 'grass roots' campaign gets feisty about GM
04 October, 2005 by Graeme O'NeillCould 'farmer power' force Australian state governments to back down on their moratoria on GM crops? Graeme O'Neill reports.
OPINION: Is it time to redesign animal agriculture?
30 September, 2005 by Shaun CoffeyOn the eve of a leading livestock conference, CSIRO Livestock Industries chief Shaun Coffey looks at why there are more questions than answers in agriculture -- and why scientists need to join in the debate.
INTERVIEW: Turbocharging for growth
29 September, 2005 by Helen SchullerCochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers.
Chemgenex expands trial to include breast and ovarian cancers
27 September, 2005 by Helen SchullerMelbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has expanded phase II clinical trials of its investigational anti-cancer drug Quinamed to include patients with breast and ovarian cancer.
NeuroSolutions signs $100,000 contract
27 September, 2005 by Ruth BeranUK-based NeuroSolutions, the fully owned subsidiary of neurology-focused biotech NeuroDiscovery (ASX:NDL), is to receive about AUD$100,000 for providing electrophysiology services to drug development company Senexis over the next four months.
Box Hill Institute hires former AusBiotech CEO
27 September, 2005 by Ruth BeranMelbourne TAFE college Box Hill Institute (BHI) has engaged former AusBiotech executive director and CEO Dr Anthony Coulepis to advise on the delivery of education and training through its recently launched BioSkills initiative.
Pharmaxis launches global capital raising
26 September, 2005 by Helen SchullerSydney-based drug developer Pharmaxis (ASX:PXS) has opened a public offering on the sale of ordinary shares in US and a placement of shares in Australia to fund further clinical trials of its lead drugs Bronchitol and Aridol.
US buy boosts Life Therapeutics' plasma business
26 September, 2005 by Helen SchullerSydney-based Life Therapeutics (ASX:LFE) has acquired privately-held California-based Pyramid Biological for US$13 million, plus assumption of US$7 million debt, increasing its stake in the global plasma supply industry.
Epitan founder: why I'm not leaving biotech
26 September, 2005 by Helen SchullerEpitan (ASX:EPT) founder and former managing director and CEO Dr Wayne Millen is set to retire as chairman of the board at the end of October but intends to continue to play a role in the company and the biotech sector.
From A to Z: Amrad wants Zenyth as new name
26 September, 2005 by Ruth BeranMelbourne's Amrad Corporation (ASX:AML) has proposed that its name be changed to Zenyth Therapeutics.
Mesoblast stem cell trial gets ethics approval
23 September, 2005 by Ruth BeranAdult stem cell specialist Mesoblast (ASX:MSB) has received ethics approval to commence its first human orthopaedic trial.
